ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Rheumatoid arthritis (RA)"

  • Abstract Number: 2152 • 2012 ACR/ARHP Annual Meeting

    Inhibition of Fucose Incorporation Abrogates the Development of Arthritis by Suppressing the Inflammatory Macrophage Development and TNF-α Production

    Jun Li1, Hui-Chen Hsu2, PingAr Yang1, Qi Wu1, David M. Spalding3, W. Winn Chatham4, Robert P. Kimberly5, S. Louis Bridges Jr.6 and John D. Mountz7, 1Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 2Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Clinical Immunology and Rheum, University of Alabama at Birmingham, Birmingham, AL, 4University of Alabama at Birmingham, Birmingham, AL, 5Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 6Clinical Immunology & Rheum, University of Alabama at Birmingham, Birmingham, AL, 7Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL

    Background/Purpose: Fucosylation, catalyzed by fucosyltransferases (Futs), is an important glycosylation process involved in inflammation, cell death, and differentiation. We have observed an extremely high positive correlation…
  • Abstract Number: 1584 • 2012 ACR/ARHP Annual Meeting

    Validity of the Nurses Health Study II Physical Activity Questionnaire (NHSPAQ) in Estimating Physical Activity in Adults with Rheumatoid Arthritis (RA)

    Maura D. Iversen1, Thomas Quinn2 and Michelle A. Frits3, 1Department of Physical Therapy, Movement & Rehabilitation Sciences, Northeastern University, Boston, MA, 2Biology, Northeastern University, Boston, MA, 3Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: An accurate assessment of physical activity (PA) is critical to manage rheumatoid arthritis (RA). Accelerometry is an objective measure of PA but is not…
  • Abstract Number: 652 • 2012 ACR/ARHP Annual Meeting

    Serum Rituximab Levels and Efficiency of B-Cell Depletion: Differences Between Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

    Venkat Reddy1, Sara Croca2, Delia Gerona3, Inmaculada De La Torre Ortega3, David A. Isenberg4, Maria Leandro2 and Geraldine Cambridge5, 1Rheumatology, University College London, London, United Kingdom, 2Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, 3Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, 4Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 5Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom

    Background/Purpose: Variability in rituximab-induced B-cell depletion (BCD) occurs in a significant number of patients with Systemic Lupus Erythematosus (SLE) and to a lesser extent in…
  • Abstract Number: 352 • 2012 ACR/ARHP Annual Meeting

    Meta-Analysis: Influence of Methotrexate, Anti-TNF and Rituximab On the Immune Response to Influenza and Pneumococcal Vaccines in Patients with Rheumatoïd Arthritis

    Charlotte Hua1, Thomas Barnetche2, Bernard Combe3 and Jacques Morel4, 1Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 2Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, 3Rheumatology, Hopital Lapeyronie, Montpellier, France, 4Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France

    Background/Purpose: Vaccines against influenza and streptococcus pneumonia are currently recommended for patients with rheumatoid arthritis (RA). This meta-analysis assesses current literature data on the impact…
  • Abstract Number: 2665 • 2012 ACR/ARHP Annual Meeting

    Metabolic Reprogramming of Autoimmune T Cells in Rheumatoid Arthritis

    Zhen Yang1, Hiroshi Fujii2, Shalini Mohan1, Jorg J. Goronzy1 and Cornelia M. Weyand3, 1Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 2Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, 3Medicine, Stanford University School of Medicine, Stanford, CA

    Background/Purpose: In RA, autoimmunity precedes clinical symptoms by a decade and persists unabated even when downstream inflammation is well controlled; exposing lymphocytes to chronic stimulation…
  • Abstract Number: 2129 • 2012 ACR/ARHP Annual Meeting

    Dickkopf-1 Is Increased in Rheumatoid Arthritis of Recent Onset and Might Be a New Biomarker of Structural Progression. Data From the Espoir Cohort

    Raphaèle Seror1, Stephan Pavy2, Thierry Schaeverbeke3, Alain Saraux4, Xavier Mariette5 and Corinne Miceli-Richard1, 1Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, 2Hopital Bicetre, Paris, France, 3Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, 4Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, 5Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France

    Background/Purpose: Dickkopf-1 (DKK-1) is an inhibitory protein of the Wnt signalling pathway that could be involved in subchondral bone erosions occurring in rheumatoid arthritis (RA).…
  • Abstract Number: 1338 • 2012 ACR/ARHP Annual Meeting

    Anti-Tumor Necrosis Factor Therapy Reduces Serum Levels of Chemerin in Rheumatoid Arthritis: A New Mechanism by which Anti-Tumor Necrosis Factor Might Reduce Inflammation

    M.M. Herenius1, A.S.F. Oliveira1, C.A. Wijbrandts1, D. Gerlag1, Paul P. Tak2 and Maria C. Lebre3, 1Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 2Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands, 3Clinical Immunology and Rheumatology & Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: Chemerin is a specific chemoattractant for macrophages and dendritic cells (DC). In addition, it can rapidly stimulate macrophage adhesion to extracellular matrix proteins and…
  • Abstract Number: 490 • 2012 ACR/ARHP Annual Meeting

    12- and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/ Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis

    Josef S. Smolen1, Douglas E. Schlichting2, Kimberly L. Sterling3, Edward Keystone4, Peter Taylor5, Mark C. Genovese6, Louise Johnson7, Juan C. Rizo Rodriguez8, Chin H. Lee2 and Carol L. Gaich3, 1Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Eli Lilly and Company, Indianapolis, IN, 3Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, 4University of Toronto, Toronto, ON, Canada, 5Kennedy Institute of Rheumatology, London, United Kingdom, 6Division of Rheumatology, Stanford University, Palo Alto, CA, 7PharmaNet/i3, Eden Prairie, MN, 8Clinical Investigation, Centro de Alta Especialidad en Reumatología e Investigación del Potosí, San Luis Potosi, San Luis Potosi, Mexico

    Background/Purpose: Baricitinib (formerly, LY3009104/INCB028050) is a novel, oral inhibitor of the JAK1 and JAK2 in the JAK-STAT pathway known to be of importance in the…
  • Abstract Number: 345 • 2012 ACR/ARHP Annual Meeting

    Predictive Software-Based Mathematical Modeling: A Novel Approach to Development of Oral Therapies for Rheumatoid Arthritis – Validation in a Murine Collagen Induced Arthritis Model

    Gurkirpal Singh1, Robinson Vidva2, Prashant Nair2, Saumya Radhakrishnan2, Pradeep Fernandes2, Taher Abbasi2, Canio Refino3, Jay Dela Cruz3 and Shireen Vali2, 1Gastroenterology/Hepatology, Stanford University School of Medicine, Palo Alto, CA, 2CellWorks Group, Saratoga, CA, 3InTouch Bio, Alameda, CA

    Background/Purpose: Rheumatoid Arthritis (RA) involves complex interactions of multiple cell systems, cytokines and mediators, and interlinked signaling.  While molecularly-targeted therapies manipulate specific interactions, it is…
  • Abstract Number: 2101 • 2012 ACR/ARHP Annual Meeting

    How Much Can Patient Reported Outcomes Improve Among Rheumatoid Arthritis Patients Who Have a Clinical Response to Biologic Therapy but Have Not Attained Low Disease Activity?

    Jeffrey R. Curtis1, Ying Shan, Jie Zhang1, Jeffrey D. Greenberg3 and George W. Reed4, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2New York Hospital for Joint Disease, New York, NY, 3University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: Current treat-to-target (T2T) recommendations suggest that rheumatoid arthritis (RA) patients should strive for remission or low disease activity (LDA) as a goal. Treatment changes…
  • Abstract Number: 1326 • 2012 ACR/ARHP Annual Meeting

    Efficacy of Different Biologic Agents for Improving Physical Function As Measured by the Health Assessment Questionnaire: A Meta-Analysis with Indirect Comparisons

    Lillian J. Barra1, Andrew Ha2, Louise Sun3, Catarina Fonseca4 and Janet E. Pope5, 1Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, 2The University of Toronto, Toronto, ON, Canada, 3University of Ottawa, Ottawa, ON, Canada, 4Universidade de Lisboa, Lisbon, Portugal, 5Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada

    Background/Purpose:   The Health Assessment Questionnaire (HAQ) is a patient-centred, validated measure of physical function. It is predictive for disability, morbidity and mortality. The efficacy…
  • Abstract Number: 494 • 2012 ACR/ARHP Annual Meeting

    Are There Gender Specific Differences in Patient Characteristics At Initiation of Biologic Treatment in Rheumatoid Arthritis?

    William Bensen1, Denis Choquette2, Isabelle Fortin3, Alice V. Klinkhoff4, Susan M. Otawa5 and Hayssam Khalil6, 1St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, 2Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 3Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, 4The Mary Pack Arthritis Ctr, Vancouver, BC, Canada, 5Medical Affairs, Janssen Inc., Toronto, ON, Canada, 6Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

    Background/Purpose: The prevalence of rheumatoid arthritis (RA) is 2-4 times higher in women compared to men depending on age. Furthermore, in women RA incidence increases…
  • Abstract Number: 195 • 2012 ACR/ARHP Annual Meeting

    Inflammatory Arthritis in Patients with Myelodysplastic Syndrome: French Multicenter Retrospective Study

    Arsene Mekinian1, Olivier Decaux2, Geraldine Falgarone3, Thorsten Braun Sr.4, Eric Toussirot5, Loic Raffray6, Bruno Gombert7, Bruno de Wazieres8, Anne Laure Buchdaul9, Jean-Marc Ziza10, David Launay11, Guillaume Denis12, Serge Madaule13, Pierre Fenaux14 and Olivier Fain15, 1Internal Medicine, Jean Verdier Hospital, Bondy, FL, France, 2Department of Internal Medicine, Rennes University Hospital, Rennes, France, 3Rheumatology, Hopital avicenne, Paris, France, 4Hematology, Avicenne hospital, Bobigny, France, 5Université de Franche Comté , CHRU, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France, 6Internal Medicine, CHU de Bordeaux, Bordeaux, France, 7Internal Medicine, La Rochelle hospital, La Rochelle, France, 8Internal Medecine, CHU de Nimes, Nimes, France, 9Internal Medicine, Douai hospital, Douai, France, 10Rheumatology, Croix Saint Simon Hospital, Paris, France, 11Internal Medicine, Claude Huriez University Hospital, Lille, France, 12Internal Medicine, Rochefoucault hospital, Rochefoucault, France, 13Rheuamtology, Albi hospital, Albi, France, 14Hematology, Avicenne Hospital, France, 15Internal Medicine, Jean Verdier Hospital, Bondy, France

    Inflammatory arthritis in patients with myelodysplastic syndrome: French multicenter retrospective study.For the Société Nationale Française de Médecine Interne (SNFMI), the CRI (Club Rhumatismes Inflammation) and…
  • Abstract Number: 2107 • 2012 ACR/ARHP Annual Meeting

    Assessing Subclinical Synovitis in Rheumatoid Arthritis: Arthrosonographic Findings in Patients with Good Response to Therapy

    Matthias Witt1, Felix Mueller2, Axel Nigg2, Christiane Reindl3, Hendrik Schulze-Koops2 and Mathias Grunke2, 1Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, 2Division of Rheumatology, Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, 3Division for Rheumatology, Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany

    Background/Purpose: Treat-to-target is a key principle in rheumatoid arthritis. Composite scores such as the DAS-28 help to monitor disease activity and response to therapy. However,…
  • Abstract Number: 1310 • 2012 ACR/ARHP Annual Meeting

    Analysis of Anti-JC Polyomavirus T-Cell Immune Response with JC-Feron in Patients with Rheumatoid Arthritis Treated with Rituximab or Anti-TNF

    Raphaèle Seror1, Houria Chavez2, anne-Aurélie Mazet3, Jeremie Sellam4, Bruno Fautrel5, Maxime Dougados6, Yassine Taoufik2 and Xavier Mariette7, 1Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, 2Biologic Immunology, Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin Bicetre, France, 3Virology, Bicetre university hospital, LE Kremlin-Bicetre, France, 4Rheumatology, Hopital Saint-Antoine, Pierre et Marie Curie University Paris 6, AP-HP, 75012, France, 5Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, 6Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 7Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France

    Background/Purpose: Some cases of progressive multifocal leukoencephalopathy (PML) have been described in patients with autoimmune diseases with profound immunosuppression, due to replication of JC polyomavirus…
  • « Previous Page
  • 1
  • …
  • 53
  • 54
  • 55
  • 56
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology